BaseLaunch

Join us for "Different business models in an ever-challenging funding landscape – The legal view," a biotech networking event with Walder Wyss Ltd. and VISCHER.   As the biotech funding landscape shifts, companies are exploring new approaches like early platform deals and "build-to-buy" setups. This event will dive into the legal aspects of structuring these models, managing terminations, and understanding typical timelines.   👉 Register here: https://lnkd.in/eAk_n_dr ❔ You can submit your questions in advance as a comment on this post or through this form: https://lnkd.in/eYPe2DXX   Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation

👉 MT-act, one of our portfolio companies announces the expansion of its Advisory Board members, welcoming Dr. Alexander Flohr and Constance Verdonk MD. These esteemed professionals bring a wealth of experience and diverse expertise in chemistry, biotech ventures and cardiology, which will strengthen both strategic direction and growth.

👉 Scaling your biotech startup can be very complex. Discover key strategies for biotech companies transitioning from early- to late-stage. In our latest blog post, Martyna Wroblewska, Manager of Innovation talked with Peter Mozerov, Senior Manager Life Science Strategy at KPMG Switzerland, on how to manage the commercial and competitive aspects of moving from early-stage development to late-stage success.    Learn about:  - Building the right company structure from the first day  - Key success factors for biotech startups  - Overcoming hurdles like hiring, regulatory timelines, and market understanding  - How to plan for future disruptions in the biotech sector    🎥 Watch the full interview 👇 📃 Read more: link in the comment    Stephan Emmerth, Neil Goldsmith, Virginia Ballotta, Lenka Michalkova  #AccelerateInBasel #Therapeutics #Biotech #Innovation 

Alentis Therapeutics, a clinical-stage biotech and one of our portfolio companies, has received FDA IND clearance for ALE.P02, a first-in-class anti-Claudin-1 ADC. This novel therapy, targeting squamous cancers, will enter a Phase 1/2 clinical trial in Q1 2025. ALE.P02 represents a breakthrough for patients with CLDN1+ tumors, such as those originating in the head, neck, and lungs, who need new treatment options. 👉 Read more: https://lnkd.in/ePKugSqC Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation

👉 Join us at Lonza’s i2i Academy. If you're in biopharmaceutical development and/or looking to de-risk your mammalian or bioconjugate molecule candidate, this is the event for you. BaseLaunch will present "How BaseLaunch helps launch and build biotech companies" alongside industry leaders. Event highlights include expert talks, case studies, a tour of Lonza’s biologics drug product labs, and the opening of Lonza Stucki’s GMP Analytics new building H. 👉 Register here: https://lnkd.in/ghjeeJvd Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation

https://lnkd.in/d-JbDqEm

🔍 Looking for an experienced drug developer to join an emerging biotech as COO We’re seeking an experienced drug developer to lead operations at an emerging, solidly capitalized, biotech startup in Basel. Help shape the future of rare disease treatments and make a meaningful impact. 👉 Learn more and apply: https://lnkd.in/ed236RUR Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation

🔔 We are pleased to welcome MT-act to the BaseLaunch portfolio. MT-act, spun out from the Institute of Human Genetics and CNRS in Montpellier, is developing therapies for age-related diseases by targeting microtubule-modifying enzymes. The team recently published results in Science Translational Medicine showing therapeutic benefits in a preclinical model of HFpEF. We welcome the founders, Dr. Siem van der Laan (CEO) and Dr. Khaled Hached (COO), and look forward to working with them! 👉 Read more here: https://lnkd.in/enjwBEPn Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta, #Biotech #Innovation #AccelerateInBasel #Therapeutics

We’re pleased to welcome Hoffmann & Partner as our new domain partner. With their strong expertise in mergers & acquisitions (M&A) and CFO services, they're an excellent addition to our collaborative network.    We look forward to a successful partnership.    👉 Read more: https://lnkd.in/eVyEQFtR   Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #Innovation #LifeSciences #Startups #Partnership 

🕒 Application deadline: 4 September 🕒 The application deadline is approaching. We welcome projects at any stage - whether seed, pre-seed or early concept. Our support includes financing, access to partners, and senior drug development expertise. If you're unsure if your project is at the right stage, feel free to reach out for guidance. 👉 Apply now: https://lnkd.in/e8aP-3Z Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation